NVUS Novus Therapeutics Inc.

Novus Therapeutics to Present at H.C. Wainwright and Cantor Global Investment Conferences

Novus Therapeutics, Inc. (“Novus”) (NASDAQ: NVUS), a clinical stage biotechnology company targeting the CD40L pathway to develop potential treatments for organ or cell-based transplant, autoimmune and neurodegenerative diseases, today announced that David-Alexandre C. Gros, M.D., Chief Executive Officer, will present a corporate overview to virtual audiences this week at the H.C. Wainwright & Co. 22nd Annual Global Investment Conference and at the Cantor Virtual Global Healthcare Conference.

Conferences Details

Event:

 

H.C. Wainwright 22nd Annual Global Investment Conference (virtual)

Date:

 

Wednesday, September 16th

Time:

 

3:30 p.m. ET

 

 

 

Event:

 

Cantor Virtual Global Healthcare Conference (virtual)

Date:

 

Thursday, September 17th

Time:

 

12:00 p.m. ET

Live webcasts of both presentations can be accessed by visiting the “Events and Presentations” tab of the investor section of the Novus website at . A replay of the webcasts will be archived for 30 days following the conference.

About Novus Therapeutics

Novus Therapeutics, Inc. is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people requiring an organ or cell-based transplant, and for people with autoimmune and neurodegenerative disease. Novus is headquartered in Irvine, Calif. For more information, please visit the company’s website at . Follow Novus Therapeutics on social media: and .

Forward-Looking Statements

This press release contains forward‐looking statements that involves substantial risks and uncertainties. Any statements about the company’s future expectations, plans and prospects, including statements about its strategy, future operations, development of its product candidates, and other statements containing the words “believes,” “anticipates,” “plans,” “expects,” “estimates,” “intends,” “predicts,” “projects,” “targets,” “looks forward,” “could,” “may,” and similar expressions, constitute forward‐looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, although not all forward‐looking statements include such identifying words. Forward‐looking statements include, but are not limited to statements regarding: risks related to market conditions; expectations regarding the timing for the commencement of future clinical trials; expectations regarding the success of clinical trials; the rate and degree of market acceptance and clinical utility of the company’s products; the company’s estimates regarding expenses and cash runway; and the impact of the ongoing coronavirus pandemic. Actual results may differ materially from those indicated by such forward‐looking statements as a result of various factors. These risks and uncertainties, as well as other risks and uncertainties that could cause the company’s actual results to differ significantly from the forward‐looking statements contained herein, are discussed in our quarterly 10-Q, annual 10-K, and other filings with the SEC, which can be found at . Any forward‐looking statements contained in this press release speak only as of the date hereof and not of any future date, and the company expressly disclaims any intent to update any forward‐looking statements, whether as a result of new information, future events or otherwise.

EN
15/09/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Novus Therapeutics Inc.

 PRESS RELEASE

Novus Therapeutics Announces One-for-Eighteen Reverse Stock Split

IRVINE, Calif.--(BUSINESS WIRE)-- Novus Therapeutics, Inc. (NASDAQ : NVUS) today announced that it has filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation to effect a reverse stock split of its issued and outstanding common stock, at a ratio of 1-for-18. The effective time of the reverse stock split will be 12:01 a.m. (Eastern Time) on October 5, 2020. Novus common stock will begin trading on a split-adjusted basis commencing upon market open on October 5, 2020. As a result of the reverse split, every 18 shares of Novus’s issued and outstanding common sto...

 PRESS RELEASE

Novus Therapeutics to Present at H.C. Wainwright and Cantor Global Inv...

IRVINE, Calif.--(BUSINESS WIRE)-- Novus Therapeutics, Inc. (“Novus”) (NASDAQ: NVUS), a clinical stage biotechnology company targeting the CD40L pathway to develop potential treatments for organ or cell-based transplant, autoimmune and neurodegenerative diseases, today announced that David-Alexandre C. Gros, M.D., Chief Executive Officer, will present a corporate overview to virtual audiences this week at the H.C. Wainwright & Co. 22nd Annual Global Investment Conference and at the Cantor Virtual Global Healthcare Conference. Conferences Details Event:   H.C. Wainwright 22nd Ann...

 PRESS RELEASE

Novus Therapeutics Announces Acquisition of Anelixis Therapeutics

IRVINE, Calif. & BOSTON--(BUSINESS WIRE)-- Novus Therapeutics, Inc. (“Novus”) (NASDAQ: NVUS) today announced it has completed the acquisition of Anelixis Therapeutics, Inc. (“Anelixis”), a privately held clinical stage biotechnology company developing a next generation anti-CD40 Ligand (CD40L) antibody as a potential treatment for organ and cellular transplantation, autoimmune diseases, and neurodegenerative diseases. Concurrent with the acquisition of Anelixis, Novus entered into a definitive agreement for the sale of non-voting convertible preferred stock (the “Preferred Stock”) in a private...

 PRESS RELEASE

Novus Therapeutics Announces Topline Results of Phase 2a Clinical Tria...

IRVINE, Calif.--(BUSINESS WIRE)-- Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat, today announced topline results from the company’s exploratory phase 2a clinical trial of OP0201 in acute otitis media (study C-006). Study C-006 was a phase 2a, single center, double-blind, randomized, placebo-controlled, parallel group clinical trial to assess the safety, tolerability, and efficacy of 20 mg per day intranasal OP0201 as an adjunct therapy to oral antibiotic in the treatment of a...

 PRESS RELEASE

Novus Therapeutics Reports First Quarter 2020 Financial Results

IRVINE, Calif.--(BUSINESS WIRE)-- Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat, today announced financial results for the quarter ended March 31, 2020. Operational Highlights Raised gross proceeds of approximately $5.8 million through the exercise of outstanding warrants in January 2020 Completed enrollment of OP0201 phase 2a clinical trial in acute otitis media (study C-006) in March 2020 Upcoming Milestones Topline results of OP0201 phase 2a clinical trial in ac...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch